MetaCap

Celularity (CELU) vs eXoZymes (EXOZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

Celularity (CELU) has outperformed eXoZymes (EXOZ) over the past year, losing 32.1% versus a loss of 59.7%. eXoZymes is the larger company by market cap ($49.0 million vs $47.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CELU-32.09%EXOZ-59.68%
+31%-23%-77%
Oct 8, 20251 yearOct 8, 2026
CELU-40.65%EXOZ-52.61%
+89%+3%-83%
Nov 11, 20245 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CELU versus EXOZ key metrics
MetricCELUEXOZ
Share price$1.46$5.27
Market cap$47.38M$49.04M
1-day change-0.68%-4.87%
YTD return+31.53%-51.65%
1-year return-32.09%-59.68%
5-year return-97.97%—
EPS (TTM)$-2.73$-1.19
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$2.55$18.40
52-week low$0.56$4.35
Distance from 52-week high-42.75%-71.36%
Analyst consensus—strong_buy
Average volume3.89M6.97K
Shares outstanding32.45M9.30M
Employees11532
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CELU has outperformed EXOZ by 27.6 percentage points over the past year.

About Celularity

CELU stock →

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.

Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees

About eXoZymes

EXOZ stock →

eXoZymes, Inc. operates as a development stage biotechnology company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 32 employees

CELU vs EXOZ FAQ

Which is bigger, Celularity or eXoZymes?

eXoZymes (EXOZ) is larger, with a market capitalization of $49.04M compared with $47.38M for Celularity (CELU).

Which stock has performed better over the past year, CELU or EXOZ?

CELU returned -32.09% over the past 12 months, compared with -59.68% for EXOZ (price return, excluding dividends). Past performance does not predict future results.

Are Celularity and eXoZymes in the same industry?

Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Celularity and Biotechnology: Biological Products (No Diagnostic Substances) for eXoZymes.

More comparisons